GH
FATE icon

Grosvenor Holdings’s Fate Therapeutics FATE Stock Holding History

Grosvenor Holdings’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$40.2M Hold
1,037,256
– – 7.85% 5
2021
Q4 		$60.7M Hold
1,037,256
– – 6.28% 6
2021
Q3 		$61.5M Sell
1,037,256
-4,251
-0.4% -$333K 7.53% 3
2021
Q2 		$90.4M Sell
1,041,507
-82,069
-7% -$6.61M 8.98% 3
2021
Q1 		$92.6M Sell
1,123,576
-335,941
-23% -$32.2M 6.81% 5
2020
Q4 		$133M Sell
1,459,517
-876,233
-38% -$54.4M 7.23% 2
2020
Q3 		$93.4M Hold
2,335,750
– – 6.88% 3
2020
Q2 		$80.1M Buy
2,335,750
+128,500
+6% +$3.83M 7.46% 3
2020
Q1 		$49M Sell
2,207,250
-78,464
-3% -$1.98M 5.57% 11
2019
Q4 		$44.7M Hold
2,285,714
– – 7.45% 9
2019
Q3 		$35.5M Buy
+2,285,714
New +$43.8M 6.41% 8

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Grosvenor Holdings's FATE Position: Q1 2022 in Review

Grosvenor Holdings held its Fate Therapeutics (FATE) position steady in Q1 2022 at 1,037,256 shares worth $40.2M. The position accounts for 7.85% of the portfolio, ranked #5.

Grosvenor Holdings first reported a position in FATE in Q3 2019 and has held it in 11 quarters since. The position peaked at $133M in Q4 2020. 250 funds tracked by Wall St. Rank hold FATE as of Q1 2022.

  • Grosvenor Holdings held 1,037,256 shares of Fate Therapeutics worth $40.2M as of Q1 2022.
  • Grosvenor Holdings left its Fate Therapeutics share count unchanged in Q1 2022.
  • Fate Therapeutics made up 7.85% of Grosvenor Holdings's portfolio in Q1 2022, its #5 holding.
  • Grosvenor Holdings first reported a position in Fate Therapeutics in Q3 2019 and has held it in 11 quarters since.
  • Grosvenor Holdings's Fate Therapeutics position peaked at $133M in Q4 2020.
  • 250 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2022.

Based on Grosvenor Holdings's 13F filing for Q1 2022, filed 16 May 2022.